Bromide

Bromide

SCHEMBL4516274

CC(C)(C)OC(=O)CN1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)OCc2ccccc2)CC1.[Br-].[Na+].[Na+].[Na+]

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 known ✓ P08172 1/20 0.38
CHRM4 known ✓ P08173 1/20 0.38
CHRM1 known ✓ P11229 1/20 0.38
CHRM3 known ✓ P20309 1/20 0.38
ALDH1A1 P00352 4/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PLA2G10 O15496 1/20 0.41
PLA2G5 P39877 1/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
MAPK1 P28482 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
POLB P06746 1/20 0.40
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2811174 0.92 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2PLA2G10PLA2G5MEN1
SCHEMBL25422192 0.92 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2PLA2G10PLA2G5MEN1
SCHEMBL15982318 0.92 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2PLA2G10PLA2G5MEN1
SCHEMBL12004770 0.92 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2PLA2G10PLA2G5MEN1
SCHEMBL28519312 0.92 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2PLA2G10PLA2G5MEN1
Bromide SCHEMBL4656223 0.91 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2PLA2G10PLA2G5MEN1
SCHEMBL16749989 0.87 HTT (0.46) ALDH1A1SMN1; SMN2PLA2G10PLA2G5MEN1
SCHEMBL18840380 0.87 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2PLA2G10PLA2G5MEN1
SCHEMBL14190560 0.85 EGFR (0.46) ALDH1A1SMN1; SMN2PLA2G10PLA2G5MEN1
SCHEMBL18286738 0.85 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2PLA2G10PLA2G5MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703937-B2 Metal complexes of tetraazamacrocycle derivatives MALLINCKRODT LLC (US) 2014-04-22 US disclosed
US-20120277421-A1 Metal Complexes of Tetraazamacrocycle Derivatives MALLINCKRODT LLC (US) 2012-11-01 US disclosed
US-8193347-B2 Metal complexes of tetraazamacrocycle derivatives MALLINCKRODT LLC (US) 2012-06-05 US disclosed
US-20090036674-A1 Metal Complexes of Tetraazamacrocycle Derivatives MALLINCKRODT US POOL LLC 2009-02-05 US disclosed
EP-1999118-A2 METAL COMPLEXES OF TETRAAZAMACROCYCLE DERIVATIVES Mallinckrodt, Inc. (US) 2008-12-10 EP disclosed
WO-2007106546-A2 METAL COMPLEXES OF TETRAAZAMACROCYCLE DERIVATIVES MALLINCKRODT INC. (US) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277421-A1 Metal Complexes of Tetraazamacrocycle Derivatives TBCB, SOD1, TIMCC CHRM2 4625/4885CHRM4 4617/4885CHRM1 4549/4885
US-20090036674-A1 Metal Complexes of Tetraazamacrocycle Derivatives TBCB, SOD1, TIMCC CHRM2 4625/4885CHRM4 4617/4885CHRM1 4549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.